Apogee Therapeutics Secures Robust Funding for Late-Stage Clinical Push

Biotech firm Apogee Therapeutics raises $350M in upsized equity offering to fund Phase 3 trials for atopic dermatitis drug, sending shares up nearly 15%.

Biotechnology firm Apogee Therapeutics has successfully fortified its balance sheet, capitalizing on strong investor interest to raise more capital than initially targeted. The proceeds from this equity offering are earmarked to advance the company's clinical pipeline, providing crucial runway for upcoming development milestones.

Strong Market Demand Drives Upsized Offering

In response to significant investor appetite, Apogee Therapeutics increased the size of its public offering. The company priced five million shares at $70.00 each on March 25, 2026. While initial gross proceeds were projected to be approximately $300 million, this target was revised upward to around $350 million. The underwriters, a consortium including Jefferies and Guggenheim, were also granted a 30-day option to purchase up to an additional 750,000 shares.

Settlement for the offering is scheduled for March 26, 2026. Although the issuance of new shares results in some near-term dilution for existing stockholders, the market response highlighted greater confidence in the company's now-strengthened financial position to fund its research initiatives.

Capital Injects Certainty into Key Program Timeline

The financing move is strategically timed alongside progress in Apogee's lead clinical asset. The company is gearing up to initiate Phase 3 trials for zumilokibart (APG777), its investigational antibody for treating atopic dermatitis. This follows positive Phase 2 data demonstrating sustained efficacy. The pivotal late-stage study is slated to begin in the second half of 2026, with a potential market launch for the therapy currently projected for 2029.

Investors welcomed the news and the enhanced visibility it provides. Apogee's stock surged 14.83% to $83.83 following the announcement, reaching a new 52-week high.

The fresh capital ensures funding for the company's research programs well into late-stage clinical development. The next significant catalyst for investors will be on March 28, 2026, when Apogee is set to present detailed long-term data from its APEX study at the American Academy of Dermatology (AAD) Annual Meeting.